Masoumeh Shafiei - Shohaday-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Ahmad Mafi - Imam Hussein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Yalda Nilipour - Pediatric Pathology Research Center, Research Institute for Children Health, Mofid and Shohaday-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Ainaz Sourati - Shohaday-e Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Background & Objective:Gliomas are the most common type of primary intracranial tumors in adults. The expression of estrogen receptors varies in different grades of glial tumors, and some studies have suggested that this expression might have a prognostic value. It seems that estrogen receptor expression negatively correlates with the histological grade of gliomas. In the present study, we aimed to determine the expression of estrogen receptor in different glial tumors in Iranian patients and to find a possible correlation between its expression and the grade of glial tumors.Methods:The brain tumors pathology reports from 2014 to 2017 in the Pathology Department of Shohaday-e Tajrish Hospital in Tehran, Iran were evaluated and 104 different gliomas: 79 cases of astrocytoma and 25 cases of oligodendroglioma were selected. All the samples were re-evaluated by a neuropathologist in order to accurately determine the tumor grade. The immunohistochemistry was carried out to detect the expression of estrogen receptor alpha and beta on brain tumors.Results:None of the samples expressed estrogen receptor alpha. In the case of estrogen receptor beta (ERβ), all samples showed various degrees of positivity: 9% weak, 40% moderate, and 51% strong expressions. The level of ERβ expression was found to be conversely correlated with tumor grade.Conclusion:Our study demonstrated that ERβ is expressed in the majority (if not all) of the glial tumors and its expression was conversely related to the tumor grade. Because of well-tolerability and acceptable adverse effects, ER agonists might be considered as therapeutic agents for the patients with glial tumors.

Gliomas, Estrogen receptor alpha, Estrogen receptor beta, Brain tumor grade